# Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer

> **NCT00348595** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 77 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Revlimid

## Key facts

- **NCT ID:** NCT00348595
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07-20
- **Primary completion:** 2016-06-29
- **Final completion:** 2016-06-29
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2019-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00348595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00348595, "Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00348595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*